文献速递心脑血管急症

SYNTAX score II 2020 的再开发与验证:复杂冠心病血运重建个体化决策

Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation.
PubMed 文献 · Lancet · 2020-10-08
一句话结论SYNTAX score II 2020 可预测复杂冠心病患者 PCI 与 CABG 的 10 年死亡和 5 年 MACE 风险,帮助识别个体化获益人群。

本研究基于多中心随机对照 SYNTAXES 试验(85 家医院,18 国,2005–2007 年)的 10 年随访数据,纳入 de-novo 三支病变和左主干病变患者,随机 1:1 接受 PCI 或 CABG。研究开发 SYNTAX score II 2020,结合临床预后指数、治疗分配及两个预设效应修饰因子(病变类型和解剖 SYNTAX 评分),预测 10 年全因死亡和 5 年 MACE。CABG 相对 PCI 的估计治疗获益在患者间差异显著,且获益预测校准良好。

要点

  • CABG 相对 PCI 的估计治疗获益在试验人群中差异显著,获益预测校准良好。
  • 该工具可帮助心脏团队、患者及家属选择最佳血运重建策略。

适用人群与场景

  • 纳入:de-novo 三支病变和左主干冠状动脉疾病患者,来自 SYNTAXES 试验(多中心随机对照试验的延长随访)。
  • 排除:原文未提及具体排除标准。
  • 场景:心脏团队决策场景,非急诊/ICU 床旁。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:多中心随机对照试验(SYNTAXES)的二次分析,并外部验证。
  • 样本量:SYNTAX 试验 n=1800;外部验证 pooled 人群 n=3380(FREEDOM、BEST、PRECOMBAT)。
  • 中心数:85 家医院,18 个北美和欧洲国家。
  • 人群:de-novo 三支病变和左主干冠状动脉疾病患者。
  • 干预与对照:随机 1:1 接受 PCI 或 CABG。
  • 主要终点:10 年全因死亡和 5 年 MACE(全因死亡、非致命性卒中或非致命性心肌梗死的复合终点)。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验(SYNTAXES)的二次分析,附外部队列验证。
  • 证据等级或推荐强度:原文未提及。
  • 局限:原文未述局限性。

对床旁实践的改变

  • SYNTAX score II 2020 可用于预测复杂冠心病患者 PCI 与 CABG 的 10 年死亡和 5 年 MACE 风险,辅助心脏团队个体化决策。
  • 该工具可估计 CABG 相对 PCI 的绝对风险差异,帮助识别可能从 CABG 或 PCI 获益更多的个体。
  • 适用人群:de-novo 三支病变和左主干病变患者;不适用人群:原文未提及。
  • 常见陷阱:原文未提及。

指南或共识出处

  • SYNTAXES 试验(SYNTAX Extended Survival),发表于 Lancet,2020 年。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Randomised controlled trials are considered the gold standard for testing the efficacy of novel therapeutic interventions, and typically report the average treatment effect as a summary result. As the result of treatment can vary between patients, basing treatment decisions for individual patients on the overall average treatment effect could be suboptimal. We aimed to develop an individualised decision making tool to select an optimal revascularisation strategy in patients with complex coronary artery disease.

METHODS: The SYNTAX Extended Survival (SYNTAXES) study is an investigator-driven extension follow-up of a multicentre, randomised controlled trial done in 85 hospitals across 18 North American and European countries between March, 2005, and April, 2007. Patients with de-novo three-vessel and left main coronary artery disease were randomly assigned (1:1) to either the percutaneous coronary intervention (PCI) group or coronary artery bypass grafting (CABG) group. The SYNTAXES study ascertained 10-year all-cause deaths. We used Cox regression to develop a clinical prognostic index for predicting death over a 10-year period, which was combined, in a second stage, with assigned treatment (PCI or CABG) and two prespecified effect-modifiers, which were selected on the basis of previous evidence: disease type (three-vessel disease or left main coronary artery disease) and anatomical SYNTAX score. We used similar techniques to develop a model to predict the 5-year risk of major adverse cardiovascular events (defined as a composite of all-cause death, non-fatal stroke, or non-fatal myocardial infarction) in patients receiving PCI or CABG. We then assessed the ability of these models to predict the risk of death or a major adverse cardiovascular event, and their differences (ie, the estimated benefit of CABG versus PCI by calculating the absolute risk difference between the two strategies) by cross-validation with the SYNTAX trial (n=1800 participants) and external validation in the pooled population (n=3380 participants) of the FREEDOM, BEST, and PRECOMBAT trials. The concordance (C)-index was used to measure discriminative ability, and calibration plots were used to assess the degree of agreement between predictions and observations.

FINDINGS: At cross-validation, the newly developed SYNTAX score II, termed SYNTAX score II 2020, showed a helpful discriminative ability in both treatment groups for predicting 10-year all-cause deaths (C-index=0·73 [95% CI 0·69-0·76] for PCI and 0·73 [0·69-0·76] for CABG) and 5-year major adverse cardiovascular events (C-index=0·65 [0·61-0·69] for PCI and C-index=0·71 [0·67-0·75] for CABG). At external validation, the SYNTAX score II 2020 showed helpful discrimination (C-index=0·67 [0·63-0·70] for PCI and C-index=0·62 [0·58-0·66] for CABG) and good calibration for predicting 5-year major adverse cardiovascular events. The estimated treatment benefit of CABG over PCI varied substantially among patients in the trial population, and the benefit predictions were well calibrated.

INTERPRETATION: The SYNTAX score II 2020 for predicting 10-year deaths and 5-year major adverse cardiovascular events can help to identify individuals who will benefit from either CABG or PCI, thereby supporting heart teams, patients, and their families to select optimal revascularisation strategies.

FUNDING: The German Heart Research Foundation and the Patient-Centered Outcomes Research Institute.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Takahashi K, Serruys PW, Fuster V, et al. Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation. Lancet. 2020. PMID: 33038944. doi:10.1016/S0140-6736(20)32114-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。